Consumer group calls for antidiabetes drug to be withdrawnBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e3259 (Published 08 May 2012) Cite this as: BMJ 2012;344:e3259
- Jeanne Lenzer
- 1New York
A consumer group has petitioned the US Food and Drug Administration to pull the antidiabetes drug liraglutide from the market because of safety concerns. It warns that other drugs in its class may have similar effects to varying degrees.
Public Citizen’s Health Research Group, a non-profit consumer advocacy organisation based in Washington, DC, said that liraglutide (marketed as Victoza by Novo Nordisk)—a glucagon-like peptide-1 (GLP-1) analogue drug used as a once daily injection for type 2 diabetes—is associated with higher than expected rates of pancreatitis, thyroid cancer, and kidney failure.
The drug was approved by the FDA in January 2010 over the objections of an agency safety reviewer, Karen Mahoney. In its petition Public Citizen cites Mahoney’s recommendation against …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial